The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense Oligonucleotide (ASO) ...

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

According to TipRanks.com, Lebowitz is a 4-star analyst with an average return of 4.4% and a 55.7% success rate. Lebowitz covers the Healthcare sector, focusing on stocks such as Arrowhead ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

The placebo-controlled study is aimed at assessing the safety and efficacy of zodasiran in adults and adolescents with HoFH.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference ...

A 1‑for‑10 reverse stock split consolidates shares but not value. Learn how it works, why it's done, and see other recent ...

Nuveen Asset Management LLC cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 0.8% in the fourth quarter, according to the company in its most recent 13F filing ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025.